Bal Pharma Limited has delivered impressive financial performance in Q3FY26, demonstrating strong operational efficiency and growth momentum in the pharmaceutical sector. The company's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, during their meeting held on February 11, 2026.

Board Meeting Outcome and Regulatory Compliance

The Board of Directors meeting commenced at 5:00 PM and concluded at 6:15 PM on February 11, 2026, where they approved the unaudited standalone and consolidated financial results. The company has filed the outcome under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance.

Strong Quarterly Performance

The company's Q3FY26 standalone results showcase remarkable growth across key financial metrics. Net profit witnessed a substantial surge of 181.84% year-on-year, rising from ₹69.07 lakhs in Q3FY25 to ₹194.62 lakhs in Q3FY26. This exceptional performance reflects the company's improved operational efficiency and strategic execution.

Nine-Month Performance Analysis

The nine-month period ended December 31, 2025, continued to reflect positive business trends. Revenue from operations reached ₹22,697.94 lakhs, marking a 2.84% increase from ₹22,071.28 lakhs in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹305.10 lakhs, representing a healthy 39.15% growth compared to ₹219.26 lakhs in the same period last year.

Consolidated Results Highlight Group Performance

The consolidated financial results demonstrate the overall strength of Bal Pharma Limited and its subsidiaries. Consolidated revenue from operations for Q3FY26 reached ₹8,768.97 lakhs compared to ₹7,315.44 lakhs in Q3FY25. The consolidated net profit attributable to equity holders of the parent company stood at ₹177.99 lakhs in Q3FY26, significantly higher than ₹48.12 lakhs in the corresponding quarter of the previous year.

Earnings Per Share and Capital Structure

The company's earnings per share (EPS) performance reflects the strong bottom-line growth. Basic and diluted EPS for Q3FY26 stood at ₹1.22 compared to ₹0.43 in Q3FY25. For the nine-month period, EPS reached ₹1.92 versus ₹1.38 in the previous year. The paid-up equity share capital remained stable at ₹1,592.09 lakhs with a face value of ₹10 per share.

Regulatory Compliance and Audit Opinion

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The statutory auditors SSJNB & Co issued an unmodified opinion on both standalone and consolidated financial results, confirming the accuracy and compliance of the financial statements. The company operates primarily in the pharmaceuticals segment and maintains its registered office at Bommasandra Industrial Area, Bangalore.

Bal Pharma Limited has issued a postal ballot notice dated January 8, 2026, seeking shareholder approval for the appointment of Dr. Mukesh Beekamchand as Independent Director, following the company's earlier announcement of his appointment and strong Q2 financial performance.

Postal Ballot Process Details

The company has initiated the postal ballot process exclusively through electronic voting, with no physical ballot forms being distributed to shareholders. The e-voting period is scheduled as follows:

National Securities Depository Limited (NSDL) will facilitate the electronic voting process, with Mr. Parameshwar Bhat, Practising Company Secretary from Bangalore, appointed as the Scrutinizer to ensure fair and transparent conduct.

Director Appointment Details

The postal ballot seeks approval for Dr. Mukesh Beekamchand's appointment as Non-Executive Independent Director for a five-year term until February 6, 2031. Key details of the appointment include:

Dr. Mukesh was initially appointed as Additional Director by the Board on November 12, 2025, based on the Nomination and Remuneration Committee's recommendation. He has been appointed to the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee effective November 29, 2025.

Recent Financial Performance

Prior to this postal ballot announcement, Bal Pharma reported its Q2 financial results showing mixed performance:

For the half-year ended September 30, 2025, the company achieved revenue from operations of ₹13,938.46 lakhs with net profit of ₹110.48 lakhs.

Voting Process and Compliance

Shareholders can participate in the e-voting process through NSDL's platform at www.evoting.nsdl.com . The company has ensured compliance with Section 110 of the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The postal ballot notice and related documents are available on the company's website at www.balpharma.com and stock exchange websites. Voting rights will be determined based on shareholding as on the cut-off date of January 8, 2026.

The appointment of Dr. Mukesh Beekamchand is expected to strengthen the company's research and development capabilities, particularly given his extensive experience in pharmaceutical research and commercialization spanning over 25 years.